Dual antiplatelet therapy (DAPT) is prescribed to patients following coronary stenting. It is indicated to lower the risk of ischemic events. A significant number of these patients undergo noncardiac surgery and may require DAPT interruption. This poses a significant clinical dilemma because DAPT interruption exposes patients to the potential risk of stent thrombosis, perioperative myocardial infarction, or both. Conversely, continuing DAPT may be associated with excess bleeding complications.
Sun Pharma and Docplexus had organized an interactive Webinar on 24th August 2017 at 4:00 pm . In this webinar session, Dr. Rony Mathew Kadavil, Dr. Jabir Abdullakutty and Dr. Jo Joseph discussed “ Post PCI DAPT Concerns & Consensus." This is the recorded version of the Webinar.
